With the successful closing of a hefty Series B financing, Orum Therapeutics is on track to become the first company in the world to bring to the clinic a targeted protein degrader combined with antibody drug conjugate (ADC) technology.
“The Orum team has strong antibody and bioconjugation capabilities and we’ve generated exciting preclinical results with our lead molecules,” Orum CEO and founder Sung Joo Lee said in an interview with Scrip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?